ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO905

Accelerated Vaccination Schedule against HBV with Combined Hepatitis A and B Vaccine among Hemodialysis Patients: Does It Work?

Session Information

  • Dialysis: Infection
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 610 Dialysis: Infection

Author

  • Imam, Mahmoud Hamada, Faculty of Medicine Benha University, Benha, Egypt
Background

Hemodialysis patient possesses particular attributes which increase susceptibility to HBV infections. HBV vaccination significantly decreased the number of new HBV-infected patients. Using the conventional dosage schedule requires six months of vaccination. The aim of this study is to examine the result of seroprotection using the accelerated vaccination schedule in vaccination of hemodialysis patient through using combined hepatitis A and B vaccine.

Methods

In this study, 114 consecutive hemodialysis patients at New Jeddah hospital were enrolled. Their age ranged from 18 to 71 years. The inclusion criteria were [1] Age was above 18 years, [2] All patients had undetectable HBV surface antigen and antibody. Exclusion criteria included [1] A positive serum HBV surface antigen and antibody; [2] patient received a previous course of HBV vaccine, [3] patient positive for HBV surface Ag. Patients were sequentially randomized to receive either Hepatitis B recombinant DNA vaccine or to receive combined hepatitis A and B vaccine injection. Testing for HBV surface antibodies was done one and three months after completion of the mentioned dosage schedule. The primary outcome was the detection of seroprotection using serum HBV surface antibodies ≥ 10 mIU/mL. Adverse reactions were evaluated regarding both fever and post-injection pain scale.

Results

After one and three months of completion of the vaccination schedule, there were no statistically different proportion of positive seroprotected patients among both groups.

Conclusion

Accelerated vaccination schedule using combined hepatitis A and B vaccine may be equivalent to the conventional dosage of Hepatitis B.